Navigation Links
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Date:12/3/2008

registration trial, 20% if OGX-011 is licensed prior to marketing approval and 15% thereafter. In addition, Isis currently owns approximately 2% of the outstanding common stock of OncoGenex.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis' business, its drug discovery and development pipeline, and the therapeutic potential of OGX-011 for the treatment of cancer. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  The law firm McElroy, ... that it will serve as host for "Show ... the Risks of Healthcare Reform," a one-day conference ... delivery systems, reimbursement, compliance and enforcement in a ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  ...
(Date:9/17/2014)... Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... its public offering of 4,500,000 shares of its common stock ... per share. Aratana has granted the underwriters a ... 675,000 shares of its common stock. ...
(Date:9/17/2014)... CARLSBAD, Calif. , Sept. 17, 2014 /PRNewswire/ ... ) announced that it has earned a $4 ... AKAO ) associated with the initiation of ... with serious multi-drug resistant (MDR), gram-negative bacterial infections.  ... superiority study to evaluate the efficacy and safety ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
(Date:9/17/2014)... East Brunswick, NJ (PRWEB) September 17, 2014 ... its Static Application Security Testing (SAST) tool, at AppSec ... the 19th from 9 am to 6 pm at ... 2014 is one of the leading software security conferences ... SPARROW is a tool that provides developers and managers ...
(Date:9/17/2014)... Journal of Surgery ( IJS ) has announced that ... after 24 months published journal issues become available for all ... is to improve surgical knowledge and patient care and it ... will improve efforts to achieve this. , Professor David ... always been a great place for authors to publish and ...
(Date:9/17/2014)... coupled to a progressive decline in signal transduction and ... at Karolinska Institutet in Sweden. The finding, which is ... new molecular mechanism underlying age-related impairment of insulin-producing cells ... risk factors for many diseases, and type 2 diabetes ... an increased risk of developing type 2 diabetes if ...
(Date:9/17/2014)... Representatives with Capitol Pain Institute announced ... League Event at the Four Seasons in Austin, Texas. , ... honor to be a sponsor for this great event,” said ... went on to explain that the event, the Torch of ... members at the Four Seasons to honor Torch of Liberty ...
(Date:9/17/2014)... In a continuing effort to protect local athletes ... Shield of the South Shore has partnered for the ... Athletic Association to treat area fields in preparation for ... dusk, prime mosquito feeding time, the exposure to mosquito-borne ... involved in outdoor athletic activities. , Rob and Lisa ...
Breaking Medicine News(10 mins):Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:Mechanism behind age-dependent diabetes discovered 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Mosquito Shield of South Shore Again Partners with Hanover Youth Athletic Association 2
... obstacles towards progress in the developing world is the ... been seriously addressed by the public health community. ... People, Forgotten Diseases, published by ASM Press. , Some ... too long been ignored. Parasitic and bacterial diseases ...
... Ohio, April 8, 2008 Cardinal Health,Inc. (NYSE: CAH ... safety and productivity of health care, plans to release third-quarter,results ... opening of trading,on the New York Stock Exchange., The ... 1 at,8:30 a.m. EDT to discuss results of the quarter. ...
... small trial, new study finds no effect , , TUESDAY, ... don,t help prevent relapses in patients with Crohn,s disease, ... of the Journal of the American Medical Association ... lead author Dr. Brian Feagan, professor of medicine and ...
... tea have long held a place in traditional medicine in ... health and long life and for the treatment of specific ... the bodys immune functions and hold the potential for treatment ... Now a new study by Chinese scientists found that combining ...
... 8, 2008 The numbers tell the,story, Vicki Hoak, ... the Senate Aging and Youth Committee today.,The Medicaid reimbursement ... is $67,000,per person. For an acute care hospital, the ... is just $21,000., Since the Governor and legislators ...
... Light San Diego Pink Day, SAN DIEGO, April ... world,s largest grassroots network of breast cancer survivors and,activists ... San Diego Affiliate will award $960,000 in grants to ... underinsured women and men in,San Diego receive breast cancer ...
Cached Medicine News:Health News:Forgotten diseases key to lifting developing world from poverty, destitution and despair 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 3Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 2Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 3Health News:Extracts from reishi mushroom and green tea shows synergistic effect to slow sarcoma 2Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 2Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 3Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 2Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 3Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 4
Prostate biopsy transducer....
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
... high frequency (13Mhz) ... and superficial imaging. ... Hemispheric Sound Technology ... This multi-frequency transducer ...
... an excellent choice for a ... wide scan angle. With muliple ... designed for a wide view ... versatility of this transducer provides ...
Medicine Products: